Non-exclusive Drug Discount Agreement - Tamsulosin/Dutasterid
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tamsulosin/Dutasterid (ATC-Code nach WHO: G04CA52)
Opportunity Score
Why this score?
Opportunity
10 / 100
Complexity
40 / 100
Risk factors
The procedure and all agreements automatically end on 31.01.2026 due to an exclusive discount agreement. Companies cann...
No guaranteed minimum purchase quantities; revenue depends on actual prescriptions and pharmacy behavior.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- May 31, 2027
Overview
Weak opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Conclusion of non-exclusive drug discount agreements for Tamsulosin/Dutasterid (ATC G04CA52) under §130a Abs. 8 SGB V.
- Open-House model: open to all interested pharmaceutical companies meeting participation requirements.
Show full summary
Non-exclusive drug discount agreement (Open-House model) for Tamsulosin/Dutasterid (ATC G04CA52) by AOK PLUS. The procedure has been automatically terminated on 31.01.2026 due to an exclusive discount agreement, so the tender is effectively closed. No estimated value is provided. The contract was originally set to end 31.05.2027, but early termination applies.
Risks
The procedure and all agreements automatically end on 31.01.2026 due to an exclusive discount agreement. Companies cann...
No guaranteed minimum purchase quantities; revenue depends on actual prescriptions and pharmacy behavior.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company as defined in §4 Abs. 18 AMG with respect to the offered drugs.
- Must have seat in Germany, EU, or EEA (§9 Abs. 2 S.1 AMG).
Eligibility
- No exclusion grounds under GWB §§123,124.
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Drug Discount Agreement - Tamsulosin/Dutasterid
Open-House model for non-exclusive discount agreements for pharmaceutical products containing Tamsulosin/Dutasterid. All eligible pharmaceutical companies can participate. No exclusivity and no guaranteed volumes.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tamsulosin/Dutasterid (ATC-Code nach WHO: G04CA52)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 02 Dec 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 803445-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
10 / 100
Complexity
40 / 100
Risk factors
The procedure and all agreements automatically end on 31.01.2026 due to an exclusive discount agreement. Companies cann...
No guaranteed minimum purchase quantities; revenue depends on actual prescriptions and pharmacy behavior.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications